Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of inclisiran in pediatric familial hypercholesterolemia
NL-OMON59036Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inclisiran in familial hypercholesterolemia (FH), heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), sponsored by Novartis. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Vital signs and 2 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)heterozygous familial hypercholesterolemia (HeFH)homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON59036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59036.